Notably, recent studies have shown that AR blockade by enzalutamide reprograms cellular metabolism in prostate cancer cells, resulting in an increased reliance on mitochondrial oxidative phosphorylation (OXPHOS).[16, 17] In this study, our independent findings add to this understanding by demonstrating that enzalutamide treatment induces prostate cancer cells to become dependent on oxidative phosphorylation. Here, AR is linked to Familial prostate cancer.